Skip to content

Opening book details…

Can I read Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4 on EtoBox?

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4 by Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; Rasha Refai; Claire Rekacewicz; Rita Raafat Gad; Nicolas Vignier; Mohamed Abdel‐Hamid; Khaled Zalata; Pierre Bedossa; Stanislas Pol; Arnaud Fontanet; Mostafa K. Mohamed is a Medicine article available to read on EtoBox.

What is Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4 about?

## Abstract The safety and efficacy of pegylated interferon (PEG‐IFN) alfa‐2a and ribavirin were studied among patients treated for genotype 4 chronic hepatitis C. Ninety‐five patients with chronic hepatitis C genotype 4 were treated with PEG‐IFN alfa‐2a (180 μg/week) plus ribavirin (≥11 mg/kg/day) for 48 weeks. The primary end point was sustained virological response, defined as non‐detectable levels of HCV RNA at the end of follow up (week 72). The proportion with sustained virological response was 58/95 = 61.1% (95% CI = 50.5–70.9%). Side effects were generally mild, well managed by dose reductions (in 62% of patients); in only two patients were side effects sufficiently severe to require treatment interruption. Ninety percent of patients adhered to treatment up to week 12, and their sustained virological response rate was higher compared to non‐adherent (65% vs. 22%, respectively, __P__ = 0.012). None of the patients who failed to achieve 1 log reduction of viral load by week 8 (n = 15), or 2 log reduction by week 12 (n = 17), had a sustained virological response. In conclusion, sustained virological response in genotype 4 Egyptian patients treated with PEG‐IFN alfa‐2a and riba

Who reads Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; Rasha Refai; Claire Rekacewicz; Rita Raafat Gad; Nicolas Vignier; Mohamed Abdel‐Hamid; Khaled Zalata; Pierre Bedossa; Stanislas Pol; Arnaud Fontanet; Mostafa K. Mohamed
Publisher
John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley; Research Square (ISSN 0146-6615)
Published
2009
Language
EN
Field
Medicine (Health Sciences)

More by Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; Rasha Refai; Claire Rekacewicz; Rita Raafat Gad; Nicolas Vignier; Mohamed Abdel‐Hamid; Khaled Zalata; Pierre Bedossa; Stanislas Pol; Arnaud Fontanet; Mostafa K. Mohamed

Browse all works by Hesham El Makhzangy; Gamal Esmat; Mohamed Said; Maissa ElRaziky; Soheir Shouman; Rasha Refai; Claire Rekacewicz; Rita Raafat Gad; Nicolas Vignier; Mohamed Abdel‐Hamid; Khaled Zalata; Pierre Bedossa; Stanislas Pol; Arnaud Fontanet; Mostafa K. Mohamed